A Pim kinase inhibitor, please

Blood

Volumn 105, Issue 11, 2005, Pages 4158-4159

  Giles, Francis ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AP 23573; CYCLOPHILIN; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL KINASE; PHOSPHOTRANSFERASE INHIBITOR; RAPAMYCIN; S6 KINASE; SCAFFOLD PROTEIN; TEMSIROLIMUS; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1;

ANTIBIOTIC RESISTANCE; APOPTOSIS; CELL GROWTH; CELL SURVIVAL; CYTOTOXICITY; DEREGULATION; DISEASE COURSE; DRUG BINDING; DRUG TOLERANCE; ENZYME INHIBITION; ENZYME REGULATION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC CELL; HUMAN; LEUKEMIA; LYMPHOMA; MUCOSA INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TRANSLATION INITIATION;

EID: 19344375686     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2005-03-1150     Document Type: Review

References (5)

1. Panwalkar A, Verstovsek S, Giles FJ. Mammalian target of rapamycin inhibition as therapy tor hematologic malignancies. Cancer. 2004;100:657-666.
2. Huang S, Bjornsti MA, Houghton PJ. Rapamycins: mechanism of action and cellular resistance. Ca Biol Ther. 2003;2:222-232.
3. Fox CJ, Hammerman PS, Cinalli RM, et al. The serine/ threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. Genes Dev. 2003;17:1841-1854.
4. Cohen AM, Grinblat B, Bessler H, et al. Increased expression of the hPim-2 gene in human chronic lymphocytic leukemia and non-Hodgkin lymphoma. Leuk Lymphoma. 2004;45:951-955.
5. Mohi MG, Boulton C, Gu TL, et al. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci U S A. 2004;101:3130-3135.